120 results about "RGD peptide" patented technology

The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease.

Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and normeoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.

Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.

Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing αv integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing αv integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing αv integrins.

The invention discloses RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide and are shown in the general formula I. In the general formula I, R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide (wherein R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.

The inventions provide compositions and methods for nucleic acid delivery comprising IIPMA conjugated to a polyamine. These compositions have the benefit of the steric hindrance of HPMA and the nucleic acid binding capability of a polyamine. Useful polyamines for this purpose include spermine, spermidine and their analogues, and DFMO. These polyamines have the ability not only to bind nucleic acids, but also have anti-cancer effects themselves. The compounds provided can also include ligand binding domains, such as vascular endothelial growth factors, somatostatin and somatostatin analogs, transferring, melanotropin, ApoE and ApoE peptides, von Willebrand's factor and von Willebrand's factor peptides, adenoviral fiber protein and adenoviral fiber protein peptides, PD 1 and PD 1 peptides, EGF and EGF peptides, RGD peptides, CCK peptides, antibody and antibody fragments, folate, pyridoxyl and sialyl-LewisX and chemical analogs. Methods for using these compositions to achieve a therapeutic effect, including for vaccination, are also provided.

Several methods for preventing, minimizing, or delaying the incidence of posterior capsule opacification are provided. A first method involves chemically activating the surface of an implantable ocular device, such as an intraocular lens or a capsular tension ring, by grafting a chemical moiety onto the surface of the device, covalently attaching a non-cytotoxic inhibitor compound to the chemical moiety to produce an inhibitor implantable ocular device, and implanting this inhibitor implantable ocular device into the capsular bag of an eye of a patient during extracapsular cataract surgery. Appropriate inhibitor compounds include RGD mimetics, RGD peptides, and flavonoids. A second method involves surface modifying the exterior surface of a capsular tension ring by covalently attaching a mitotic inhibitor, preferably a conjugate of methotrexate and a bovine serum albumin, and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. A third method involves surface modifying the exterior surface of a capsular tension ring by coating or grafting the exterior surface with a charged polyethylamine and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. An implantable ocular device according to the invention, such as an intraocular lens or a capsular tension ring, contains a substrate with a chemical moiety grafted thereon and a non-cytotoxic inhibitor compound covalently bonded to the chemical moiety or contains a substrate modified with a mitotic inhibitor or charged polyethylamine. The inhibitor devices inhibits proliferation and migration of lens epithelial cells on the posterior capsule of the eye of the patient, thereby preventing, minimizing, or delaying the onset of posterior capsule opacification.

The invention discloses a method for preparing RGD-fatty alcohol series compounds as tumor targeting carrier materials and application thereof. The method comprises the following steps: conjugating n-octa alkyl fatty alcohol, decane-based fatty alcohol, dodecyl fatty alcohol, tetradecyl fatty alcohol, hexadecane fatty alcohol, and octadecyl fatty alcohol with RGD peptide segment respectively, and performing hydrophobic modification on the compounds to synthesize a peptide conjugated compound with different amphiphilic long-chain alkyls and RGD, namely Arg-Gly-Asp-O-CnH[2n +1] (n is equal to 8, 10, 12, 14, 16, or 18), and synthesize a compound of Gly-Gly-Asp-O-C4H29 simultaneously, thus the effectiveness of the targeting materials is further confirmed.

A high strength surgical material with improved tie down characteristics and tissue compliance formed of ultrahigh molecular weight polyethylene (UHMWPE) yarns, the suture being coated with arginine-glycine-aspartate (RGD) peptide. The suture has exceptional strength, is ideally suited for most orthopedic procedures, and can be attached to a suture anchor or a curved needle.

The invention discloses a novel lipid material. The novel lipid material is used for prolonging the circulating time and increasing the transfer amount of medicine to brain tumor tissues in a target way. The novel lipid material is characterized in that polyethylene glycol is used as a bridge, one side of the bridge is connected with cholesterol, and one side of the bridge is connected with glucose and RGD (arginine-glycine-aspartic acid) peptide, so that the lack of brain tumor targeting ability by the lipid modified by the single glucose or the RGD peptide is overcome, and the brain tumor can be effectively targeted after blood brain barrier crossing. The novel lipid material can be used for different preparation types of lipids, nanoparticles, micelles and the like; the prepared paclitaxel-carrying lipid has obvious brain tumor targeting function, and broad application prospect.

Provided herein is a medical device that includes RGD attached to the device via a spacer compound.

The invention discloses a USPIO-PLA-RGD compound, a preparation method and application thereof. The USPIO-PLA-RGD compound uses USPIO as a core, is coated by PLA outside, and is labeled as PLA-USPIO; and the USPIO-PLA-GRD compound obtained through covalently coupling carboxyl of a functional group exposed on the surface of PLA and amidogen of RGD peptide has a hydrated grain diameter of between 90 and 105 nm. The USPIO-PLA-RGD compound can be applied as magnetic resonance tumor angiogenesis targeting contrast agent. The invention realizes targeting developing by the characteristics of high affinity of an alpha v beta3 integrin receptor and ligand RGD peptide thereof, and the combination has the characteristics of high specificity, selectivity, saturation and affinity, clear biological effect and the like. The concentration of a medicament in a partial focus can be increased, and toxic and side effects can be reduced by using the ligand RGD peptide as a vector of USPIO through the mediation effect of the receptor, so that the aim of development of a targeting tumor angiogenesis living body is realized.

The present invention provides for scaffolds for growing RPE cells, comprising two or more biodegradable polymers. The present invention also provides for methods for creating a scaffold for growing RPE cells. Additionally, the present invention provides for RGD peptide linked polymer scaffolds for supporting the growth of RPE cells. The present invention provides methods of culturing RPE cells using the scaffolds produced herein. The present invention also provides methods of treating vision loss through the administration of RPE cell attached RGD peptide linked polymer scaffolds produced herein. The present invention further provides kits for treating vision loss.

The invention relates to a composite drug-loading sustained release microsphere system entrapped with quantum dots and a preparation method of the composite drug-loading sustained release microsphere system. The quantum dots and an anti-cancer medicament are entrapped in a polylactic-co-glycolic acid microsphere, and a cationic macromolecular liposome prepared from arginine-glycine-aspartic acid (RGD) peptide-modified octadecyl-quaternized lysine modified chitosan and cholesterol is coated outside the polylactic-co-glycolic acid microsphere to form a core-shell drug-loading microsphere system. The composite drug-loading microsphere system entrapped with the quantum dots and the anti-cancer medicament has the particle size being between 300 and 400nm, positive surface Zeta potential and high stability, and can be stored for at least two months after being freeze-dried. The composite drug-loading sustained release microsphere system entrapped with the quantum dots and the anti-cancer medicament has the characteristics of uniform and controllable particle size, high stability, RGD peptide modification on surface, simple preparation process and the like, and is suitable for batch production.

The invention discloses an integrin receptor target lipidosome drug carrier and a preparation method thereof, as well as an application of the drug carrier in preparing antitumor lipidosome drug. Hexadecyl fatty chain is conjugated with RGD peptide segment and is hydrophobic-modified so as to synthesize hexadecyl and RGD peptide conjugate with amphipathy, namely, Arg-Gly-Asp-X-NH-C16H33, and X is selected from valine, serine or phenylalanine. The invention introduces fat-soluble antitumor drug into the conjugate with amphipathy to obtain the antitumor target lipidosome drug, the lipidosome system can increase the concentration of the antitumor drug at the target and can reduce toxic and side effects of the antitumor drug to the non-target part, thereby improving the treatment index of the drug. The invention evaluates the antitumor activity of taxol lipidosome by using a Holland sarcoma S180 mouse as a model, the result shows that the taxol lipidosome has more excellent antitumor activity than each control group.

The invention discloses a preparation method of an RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome. The method comprises the main steps of ergosterol liposome preparation, ammonium chloride gradient formation, drug loading and co-modification. The method is simple in technology and easy to carry out, and the encapsulation rate of a drug is high; ergosterol is adopted to partially replace cis-platinum to exert efficacy, an ergosterol and cis-platinum active drug-loading liposome is obtained, the effect of resisting a lung cancer is guaranteed, the toxic and side effects of the drug are significantly reduced, and damage to human bodies is small; meanwhile, the RGD peptide and the penetrating peptide R8 serve as target heads, the targeting property is good, and the drug exertion effect is good.

The invention relates to the field of medicinal preparations, and concretely provides a targeting posterior segment eye drug delivery system, a preparation thereof and a preparation method of the preparation. The system comprises a drug and a polymer prepared from a dendritic polymer, polyethylene glycol, an RGD peptide and a CPP peptide, wherein the dendritic polymer is a 3.0-10.0 generation polyamide-amine dendritic macromolecule, the polyethylene glycol is polyethylene glycol with the molecular weight range of 2000-5000 Da, and the RGD peptide is cyclopeptide. The drug delivery system and the preparation thereof effectively conveys the drug to the pathologic position of a posterior segment eye, reduce damages of the drug to normal tissues, reduce the medication pains of patients, and increase the medication compliance of the patients.

The invention discloses a simulated retrovirus of a targeting tumor; the simulated retrovirus adopts fusion polypeptide consisting of poly-D-lysine and RGD peptide as a genomic vector, packs siRNA retrovirus recombinant and expression vector of gene which is related to the tumor and is formed by self-assembling; a preparation method thereof comprises three steps of the preparation of the fusion polypeptide, the preparation of the siRNA retrovirus recombinant and expression vector and the preparation of the simulated retrovirus; the simulated retrovirus of the targeting tumor of the invention can be targeted and positioned into tumor cells, mediates gene transfection effectively, inhibits the generation and propagation of the tumor obviously, and improves the safety and effectiveness of the tumor gene therapy; and the preparation method is simple and convenient, can be used for preparing anti-tumor drugs and has good application prospect.

The invention discloses a dual-target tumor vaccine based on a tumor endothelium marker-8 gene and a preparation method thereof. The tumor vaccine is formed by combining an eukaryon expression vector recombined by the tumor endothelium marker-8 gene with fusogenic peptide obtained by fusing a membrane penetrating peptide HIV-Tat49-57 and a RGD peptide in the manner of non covalent bonds. The preparation method thereof comprises the following steps: respectively preparing the eukaryon expression vector recombined by the tumor endothelium marker-8 genethe and the fusogenic peptide obtained by fusing the membrane penetrating peptide HIV-Tat49-57 and the RGD peptide; and then, polymerizing the eukaryon expression vector and the fusogenic peptide through electrostatic interaction to form a compound. The tumor vaccine not only reserves the advantages of polypeptide vaccine, such as safety, easy preparation and purification and the like, but also overcomes the shortages, such as small polypeptide molecule, weak immunogenicity and difficult absorption by antigen presenting cells and the like. The vaccine can inhibit the tumor angiogenesis as well as induce the apoptosis of tumor cells, thereby greatly improving the effectiveness and the safety of tumor therapy. The vaccine has wide application prospects in the field of tumor therapy.

The invention relates to a ruthenium complex, a ruthenium-RGD (arginine-glycine-aspartic acid) peptide conjugate and a preparation method and application thereof. The conjugate is obtained by couplingtwo parts including the ruthenium complex (RuM) and RGD peptide (RGDfK). A general formula of the ruthenium complex RuM is as follows: [Ru(dmp)2(X-COOH)](PF6)2, wherein X represents a ligand: 1,2-dimethyl-1H-imidazole[4,5-f][1,10]phenanthroline. The RGD peptide is a commercial reagent (RGDfK, Shanghai Qiangyao Biotechnology Company). The conjugate RuM-RGD is obtained by taking the ruthenium complex RuM and the RGD peptide RGDfK and carrying out condensation reaction. The RuM-RGD conjugate provided by the invention has a strong inhibition effect on glioma cells U87, and can be used for accumulating mitochondria of the U87 tumor cells and inhibiting tumor cell proliferation; the RuM-RGD conjugate can be used as a novel anti-tumor medicine taking a tumor cell mitochondrion as a target spot.

The invention relates to an RGD peptide modified boron drug loading system, preparation thereof and an application of the system. An RGD peptide modified boron composite material serves as a drug carrier for loading drugs. Experimental conditions are easily controlled, operation is simple, and an obtained drug loading compound has good biocompatibility, can be slowly released in a sustained manner, has pH (potential of hydrogen) and NIR (near-infrared light) double sensitive drug releasing properties, is high in release rate in low-pH value and near-infrared light irradiation environments andsuitable for microenvironments of tumor tissues, can be used for achieving synergistic effects of low-temperature photothermal therapy and chemotherapy and has application prospects in preparation oftumor targeted, imaging and synergistic therapy drugs.